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Abstract
PDGFRA mutations in the gastrointestinal (GI) tract can cause GI stromal tumour
(GIST) and inflammatory fibroid polyp (IFP). Hitherto no cell type has been identified
as a physiological counterpart of the latter, while interstitial Cajal cells (ICC) are con-
sidered the precursor of the former. However, ICC hyperplasia (ICCH), which
strongly supports the ICC role in GIST pathogenesis, has been identified in germline
KIT-mutant settings but not in PDGFRA-mutant ones, challenging the precursor role
of ICC for PDGFRA-driven GISTs. Telocytes are a recently described interstitial cell
type, CD34+/PDGFRA+. Formerly considered fibroblasts, they are found in many
organs, including the GI tract where they are thought to be involved in neurotrans-
mission. Alongside IFPs and gastric GISTs, GI wall “fibrosis” has been reported in
germline PDGFRA-mutants. Taking the opportunity offered by its presence in a
germline PDGFRA-mutant individual, we demonstrate that this lesion is sustained by
hyperplastic telocytes, constituting the PDGFRA-mutant counterpart of germline KIT
mutation-associated ICCH. Moreover, our findings support a pathogenetic relation-
ship between telocyte hyperplasia and both IFPs and PDGFRA-mutant GISTs. We
propose the term “telocytoma” for defining IFP, as it conveys both the pathogenetic
(neoplastic) and histotypic (“telocytary”) essence of this tumour, unlike IFP, which
rather evokes an inflammatory-hyperplastic lesion.
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1 | INTRODUCTION
Inflammatory fibroid polyps (IFPs) are benign, polypoid lesions usu-
ally centred in the submucosa of the gastrointestinal (GI) tract,
with a predilection for gastric antrum. They consist of a prolifera-
tion of spindle, stellate or epithelioid mesenchymal cells harboured
in a vascularized stroma, infiltrated by inflammatory cells (often
with numerous eosinophils). Immunohistochemically, the lesional
mesenchymal cells express CD34 and platelet-derived growth fac-
tor receptor alpha (PDGFRA). Most IFPs bear PDGFRA muta-
tions.1,2 A subset of GI stromal tumours (GISTs), accounting for
6%-7% of the total, also harbours PDGFRA mutations, similar to
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
Received: 8 April 2018 | Accepted: 29 May 2018
DOI: 10.1111/jcmm.13748
4856 | wileyonlinelibrary.com/journal/jcmm J Cell Mol Med. 2018;22:4856–4862.
IFPs.3 This GIST subgroup, which manifests a strong predilection
for the stomach, is frequently at least partly epithelioid and, unlike
other GISTs, is often negative or only faintly/patchy positive for
CD117.
No physiological counterpart has hitherto been described for
IFPs, although it has been suggested that they may develop from
PDGFRA-positive mesenchymal cells found along the villus mem-
brane in the small intestine.2,4 Conversely, GISTs as a whole are
commonly considered to be related to interstitial cells of Cajal
(ICCs).5 Beyond the immunophenotype shared between most GISTs
and ICCs (CD117+, DOG1+), the presence of ICC hyperplasia (ICCH)
both in human germline KIT-mutant kindreds and in mice engineered
to express KIT mutations found in human GISTs strongly supports a
relationship between ICCs and GISTs.6,7 However, to date, no ICCH
has been detected either in human germline PDGFRA-mutants or in
mice generated for the conditional expression of mutant PDGFRA,
arguing against a relationship between ICCs and PDGFRA-driven
GISTs. Conversely, GI stromal cell hyperplasia has been described in
these conditions, especially at submucosal level.7-10
Telocytes (TCs) are a type of interstitial cell, formerly named
interstitial Cajal-like cells, described in the connective tissue of sev-
eral organs, including the GI tract.11-23 For a long time, they went
unrecognized and were labelled simplistically as fibroblasts. In the GI
tract, TCs are CD34+, PDGFRA+ and CD117-, and are thought to
play a role in neurotransmission, possibly by spreading the low
waves generated by ICCs.24 A relationship between TCs and GISTs
(without genotypic distinction) or IFPs has been sometimes sug-
gested, based on shared immunohistochemical markers and/or, in
the former instance, to explain the occurrence of extragastrointesti-
nal cases.8,25
We previously published a kindred bearing a germline mutation
(CC?TT at 1957-58) that led to a Leu for Pro substitution at 653
(P653L) in PDGFRA gene.9 The proband featured GI tumours encom-
passing GISTs, IFPs (including tumours previously described as “fi-
brous tumours”26) and a lipoma, and an intramural diffuse stromal
cell proliferation, heavily affecting the submucosa, in the stomach
and proximal duodenum. We carried out a morphological and
immunophenotypical investigation of the histotype of these stromal
cells in order to establish their possible morphogenetic and/or
pathogenetic relationship with synchronous IFPs and GISTs.
2 | MATERIALS AND METHODS
2.1 | Tissue specimens
The gastric tissues investigated were from the only member of a
previously published germline PDGFRA-mutant kindred who featured
a remarkably marked stromal proliferation of the gastroduodenal wall
together with IFPs and GISTs.9 The procedures followed were in
accordance with the ethical standards of the local institutional com-
mittee on human experimentation and with the Helsinki declaration
of 1975, as revised in 1983. Informed written consent for this study
was obtained from the patient.
2.2 | Histology and immunohistochemistry
Sections from formalin-fixed, paraffin-embedded specimens were
stained with haematoxylin/eosin. The following antibodies were
employed: CD117 (DAKO, Glostrup, Denmark, rabbit polyclonal,
1:400), CD34 (Novocastra, Newcastle, UK, 1:50) and PDGFRA (sc-
338) (Santa Cruz, Santa Cruz, CA, rabbit polyclonal, 1:400) (in all
cases for 300 at room temperature). Antigen retrieval was performed
for PDGFRA (10 minutes at 97°C, in 0.01 M citrate buffer, pH 6, PT
link, DAKO). Specific preimmune sera or isotype-specific unrelated
primary antibodies were used for the control stainings. The detection
system consisted of DAKO visualization reagent (dextran polymer
conjugated with horseradish peroxidase and goat anti-rabbit and
antimouse immunoglobulins) with 3,30- diaminobenzidine chromogen
solution. Sections were counterstained with haematoxylin.
3 | RESULTS
3.1 | Histological characterization of GI wall diffuse
stromal proliferation
A proliferation of stromal tissue involved the stomach wall (Fig-
ure 1A) and proximal duodenum. It started as two bands lining the
inner and outer aspects of the submucosa. These showed a ten-
dency to merge and ultimately completely obliterate this structure
(Figure 1C). Higher magnification revealed spindle-to-polygonal
shaped cells set in a variably collagenized background, often display-
ing thin cytoplasmic processes, at times extremely long, at times
apparently interconnecting (Figure 1D). When involving muscularis
propria, they dissociated smooth muscle fascicles according to an
interstitial pattern of growth (Figure 1F). These cells were diffusely
and intensely positive for CD34 (Figure 1B and I) and PDGFRA (Fig-
ure 1E and G) but turned out to be CD 117 negative (Figure 1H).
Besides the interstitial PDGFRA-positive cells, CD34 IHC stained the
endothelial lining of vessels, including the numerous capillaries pre-
sent (Figure 1I). Conversely, CD117 revealed another population of
cells with elongated cytoplasmic processes, not highlighted by
PDGFRA IHC, either at the interface between fibrous tissue and
smooth muscle fascicles or inside the latter, in close contact with
smooth muscle cells; the only cell type stained in the fibrous inter-
muscular interstitium by CD117 IHC were mast cells (Figure 1H).
3.2 | Relationship between GI wall diffuse stromal
proliferation and IFP
Several typical IFPs were detected, histologically superimposable to
their sporadic counterpart, being composed of an admixture of
fibroblast-like CD34+ mesenchymal cells and inflammatory cells,
often with numerous eosinophils, in a myxoid collagenous back-
ground. Interestingly, IFPs stemmed from the aforementioned diffuse
stromal proliferation (Figure 2A and B) and a progressive loss of
cytoplasmic processes in the constitutive cells was found at the
interface of the two sectors, ultimately leading to the plump,
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spindled/polygonal/epithelioid stromal cells typical of PFI (Figure 2A,
C,E,F). PDGFRA positivity was maintained, albeit with an overall
decreased intensity (Figure 2D and G).
3.3 | Relationship between GI wall diffuse stromal
proliferation and GIST
Two gastric GISTs were present, whose histological features were
indistinguishable from those of their sporadic PDGFRA-mutant coun-
terpart, featuring epithelioid cytology and PDGFRA and CD117 (pat-
chy-weak) positivity, as shown in Figure 3. Notably, near the gastric
muscularis propria permeated by the previously described fibrous pro-
liferation (Figure 3B) the GIST was characterized by a cytology that
was relatively spindled (Figure 3E) compared to the overtly epithelioid
type visible in the other parts of the tumour (Figure 3H). Moreover,
unlike the nearby gastric wall, where both interstitial cells intensely
positive for either PDGFRA or CD117 were present (Figure 3C-D),
the intramural periphery of GIST was intensely positive for PDGFRA
only, with slightly focal, weak CD117 staining (Figure 3F-G). A stron-
ger, albeit patchy, CD117 positivity was present only towards the cen-
tre and in the subserosal portion of the GIST, accompanied by a
persistent intense and diffuse PDGFRA reactivity (Figure 3I-J).
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F IGURE 1 Representative examples of histological and immunohistochemical images of gastric TC hyperplasia found in PDGFRA-mutant
syndrome. A CD34+ stromal proliferation altered the structure of gastric wall, forming two thick bands along the inner and outer aspects of
submucosa, sometimes forming ill-defined nodules, and infiltrating the deeper wall layers with an interstitial pattern (A, H&E; B, CD34). At
times, the stromal proliferation obliterated submucosa (C). At higher magnification, the stromal proliferation consisted of spindle-to-polygonal
PDGFRA+ TCs set in a variably collagenized background, often displaying slender, sometimes extremely long, cytoplasmic processes
(telopodes), at times interconnecting with each other (arrows highlight some TCs whose telopodes are clearly evident due to the favourable
intersection by the histological cutting surface) (D, H&E; E, PDGFRA). The stromal proliferation with TCs (arrows, as in D and E) infiltrated
muscularis propria with an interstitial pattern, separating smooth muscle fascicles, where no PDGFRA+ TCs are observed (F, H&E; G,
PDGFRA). CD117 demonstrated ICC-IM, characteristically in close relation with smooth muscle fibres (arrowheads); mast cells (circled) were
the only CD117+ cells populating the interstitial fibrosis (H). CD34 stained not only interstitial TCs (arrows), but also the endothelial lining of
blood vessels: A small venule is evident at the centre of the picture; arrowheads indicate capillaries, identifiable because of their lumen (I).
(Scale bars: A, B: 4 mm; C: 1 mm; D; 75 lm; E: 20 lm; F; 75 lm; G: 20 lm; H: 150 lm; I: 20 lm)
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4 | DISCUSSION
We herein report a detailed morphological and immunophenotypical
analysis of the diffuse stromal proliferation described in the GI wall in
PDGFRA-mutant syndrome7 and of its relationship with IFP and GIST,
by exploiting the exceptional opportunity offered by its remarkable
manifestation, together with the presence of these tumours, in an
individual from a kindred previously published by the authors.9
As expected, germline PDGFRA mutations are able to originate
multiple IFPs and GISTs.7 However, a third type of GI lesion, consisting
of an intramural diffuse stromal proliferation variably referred to as
“submucosal fibrous thickening,” “intestinal fibrosis,” “increased sub-
mucosal connective tissue,” “thickened submucosa” or “expanded
submucosa”, has often been described in this genetic setting, both in
humans and in mice.8-10 It consists of a CD34+ stromal proliferation,
that variously involves the entire thickness of the GI tract, often heav-
ily affecting the submucosa (Figure 1A-C). In a previous paper describ-
ing PDGFRA-mutant syndrome, we found this stromal proliferation
remarkably evident in the stomach and duodenum of an individual,
demonstrating that, in the submucosa, it often consisted of two thick
bands running along its inner and outer limits; furthermore, its consti-
tutive cells were positive not only for CD34, but also for PDGFRA,
whereas both CD117 and DOG1 were negative.9 Here, besides con-
firming these characteristics, we show that these stromal cells often
display long, slender cytoplasmic processes that sometimes appear to
connect with each other (Figure 1D-G). The consistent detection of
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F IGURE 2 Representative examples of
histological and immunohistochemical
transition between TC hyperplasia and IFP
found in PDGFRA-mutant syndrome. At the
centre, a panoramic view shows an IFP
and its relation with TC hyperplasia (A,
H&E). Proceeding in a clockwise direction,
both TC hyperplasia and IFP stain
positively at CD34 IHC (B). Diverse areas
of the specimen are then shown, at higher
magnification, in the following panels,
which refer to areas encircled in grey in
panel A; this is to underline the
topographic location of the illustrated
microscopic fields to better appreciate the
transition between TC hyperplasia and IFP;
corresponding areas are connected by
arrows. Hyperplastic TCs featuring well-
developed, elongated telopodes, line the
outer aspect of submucosa (C, H&E; D,
PDGFRA). Near the base of IFP, TCs tend
to feature shorter cytoplasmic processes,
or not to feature them at all (E, H&E). TCs
eventually blur into the relatively plump
mesenchymal cells characteristic of IFP
(note the typical perivascular onion-skin
pattern and the presence of infiltrating
eosinophils, absent in TC hyperplasia);
PDGFRA positivity is maintained, albeit
less intensely than in TC hyperplasia (F,
H&E; G, PDGFRA). (Scale bars: A, B:
2 mm; C-G: 25 lm)
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these morphological features in cells positive at CD34 and at PDGFRA
IHC (we did not perform a double immunostaining for CD34 and
PDGFRA; this constitutes a limitation of our study) is coherent with
the existence of a CD34/PDGFRA double-positive cell type clearly
distinct from other cells of the interstitium that can express PDGFRA,
that is mast cells, or CD34, that is endothelial cells.27 In particular,
endothelial lining often encircles vascular lumens, a feature allowing
its clear identification without need of CD31 immunostaining, a useful
additional tool for identifying endothelial cells in questionable cases.28
Thus, the stromal cells we describe display characteristics typical of
TCs, both morphologically and immunophenotypically. In fact, TCs are
characterized by a nucleated body (whose shape varies from small oval
to triangular/polygonal or large round-to-oval, depending on the TCs’
anatomical location) that branches out into extremely long and thin
prolongations, called “telopodes”; moreover, CD34 and PDGFRA are
currently considered the most reliable markers for their immunohisto-
chemical identification.24,29 Additionally, the cells we describe are
clearly distinguishable from ICCs because of both their
immunophenotype and their compartmentalization. In fact, (i) they
stain PDGFRA+ and CD117-, unlike ICCs, which display a reciprocal
staining; (ii) they recapitulate the physiological intramural distribution
of TCs within the GI wall; (iii) in particular, they are present in the sub-
mucosa, where ICCs are not found 27 and, before completely obliterat-
ing it (Figure 1C), they form two thick bands along its inner and outer
aspects (Figure 1A-B), that is exactly where the TCs physiologically
form a monolayer24; (iv) when in the muscularis propria, they are pref-
erentially located within the interstitial “fibrosis,” whereas the
CD117+ ICCs are found always in close contact with smooth muscle
cells either at the interface between intermuscular stromal tissue and
smooth muscle fascicles or within the latter (in keeping with intramus-
cular ICC-ICC-IM-, known to be intercalated between the intramural
neurons and smooth myocytes30) (Figure 1F-H). Of note, nerve end-
ings are rarely observed in the proximity of TCs.24 On the grounds of
all these findings, it is our opinion that the GI wall diffuse stromal pro-
liferation typical of PDGFRA-mutant syndrome is sustained by hyper-
plastic TCs, constituting the “PDGFRA-driven counterpart” of ICCH
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F IGURE 3 Representative examples of
histological and immunohistochemical
transition between TC hyperplasia and
GIST found in PDGFRA-mutant syndrome.
The panoramic view shows a GIST
originating from muscularis propria, whose
smooth muscle bundles appear variously
dissociated by the presence of interstitial
TC hyperplasia, bulging on the external
side of the gastric wall (A). As in Figure 2,
higher magnification panels refer to areas
encircled in grey in panel A, so as to
underline the topographic location of the
illustrated microscopic fields to better
appreciate the transition between TC
hyperplasia and GIST; corresponding areas
are connected by arrows. Thin fibrous
bands, populated by PDGFRA+ TCs,
separate smooth muscle bundles near the
periphery of GIST (B, H&E; C, PDGFRA; D,
CD117, highlighting ICC-IM and mast
cells). GIST (right) at the interface with
muscularis propria (left) showed a relatively
spindled cell cytology (E: H&E), and
displayed an intense PDGFRA positivity (F),
but only a weak and focal CD117 staining
(G), thereby immunophenotypically
resembling the neighbouring hyperplastic
TCs rather than ICC-IM. At a relative
distance from the muscularis propria the
GIST assumed a wholly epithelioid
cytology (H, H&E), maintaining the intense
PDGFRA immunoreactivity (I) and
sometimes acquiring a comparatively
strong positivity for CD117 (J). (Scale bars:
A: 2 mm; B-J: 65 lm)
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typical of germline KIT mutations. Of note, this finding confutes the
histotype concealed by two of the terms previously used for defining
the referred stromal proliferation, that is “submucosal fibrous thicken-
ing” and “intestinal fibrosis”: In fact, TCs are decreased in conditions
determining a genuine fibrosis of GI wall such as Crohn’s disease and
ulcerative colitis.28,31
We went on to ascertain whether it was possible to detect mor-
phological and/or immunophenotypical clues potentially linking TC
hyperplasia with IFP or GIST in PDGFRA-mutant syndrome.
With regard to IFPs, we have already described examples stem-
ming from the “submucosal thickening” found in an individual
affected by PDGFRA-mutant syndrome.9 Herein, we show also that
there appears to be a gradual cytologic progression from TCs consti-
tuting the aforementioned thickening to stromal cells forming IFP,
with a gradual loss of both slender cytoplasmic processes and rela-
tive cell elongation, accompanied by the acquisition of a relatively
plumper morphology in the presence of a persisting, although overall
less intense, positivity for PDGFRA (Figure 2C-G). We therefore con-
clude that the TC hyperplasia forming the submucosal thickening
characteristic of PDGFRA-mutant syndrome, studied in this investiga-
tion, is pathogenetically related to IFP. Consequently, by analogy
with what has been inferred from ICCH in germline KIT-mutant set-
tings regarding the relationship between ICC and KIT-mutant GIST,
TC can be considered the physiological counterpart of IFP. Consis-
tently, it is noticeable that a subtype of TC, differing from the other
GI TCs because of its lack of CD34 expression, has been described
in the axes of intestinal villi both in humans and mice27 and that
intestinal IFPs, unlike gastric ones, are often CD34-.1,2
Accumulating evidence has demonstrated that GISTs encompass a
group of heterogeneous stromal tumours which, despite often sharing
some features among overall GI location, spindle or epithelioid cytol-
ogy, relatively mild atypia, low mitotic activity and immunoreactivity
for DOG1 and CD117, nevertheless differ in molecular pathogenesis
and, consequently, in anatomical distribution along GI tract, usual
cytoarchitectural characters, immunophenotype, prognosis and drug
sensitivity.3 Concerning the minority subgroup of PDGFRA-mutant
GISTs and their physiological counterpart, apart from the abovemen-
tioned lack of ICCH in PDGFRA-mutant syndrome, it is worth noting
that, unlike most other GISTs, these tumours are often CD117- or only
weakly and patchy CD117+.3 Noticeably, TCs are CD117- in the GI
tract, but may express this marker elsewhere.24,29 Moreover, TCs are
present within the muscularis propria (ie, the GI layer originating
GISTs) both physiologically 24 and, with hyperplastic characteristics, in
PDGFRA-mutant syndrome (Figures 1 and 3). Under these circum-
stances, it is remarkable that an analysis of the transition between the
gastric muscular wall and GIST in this latter condition demonstrates
that (i) hyperplastic PDGFRA+ CD117- TCs are present in the muscu-
laris propria close to the GISTs, along with physiological PDGFRA-
CD117+ ICC-IM (Figure 3A-D); (ii) the periphery of the GIST close to
muscularis propria shows a relatively spindled cytology together with
an intense PDGFRA positivity but only a weak and focal CD117 stain-
ing, characteristics which, in relation to the two types of neighbouring
interstitial cells, globally recall TCs rather than ICCs (Figure 3A,E-G); (iii)
a wholly epithelioid cytology is reached, sometimes flanked by a rela-
tively strong CD117 immunoreactivity, only at a certain distance from
muscularis propria (where PDGFRA positivity is nevertheless pre-
served) (Figure 3A,H-J). Considering the hyperplastic condition of TCs
in PDGFRA-mutant syndrome, we believe that this evidence supports a
relationship of TCs also with PDGFRA-mutant GISTs.
Differences in TC features, possibly concealing different TC sub-
populations and varying with both GI segment and GI wall layer,24
together with possible site-specific differences in gene expression,32
could explain how TCs as a whole can originate diverse tumour
types, and why, unlike IFPs, PDGFRA-mutant GISTs show a strong
(albeit not entirely exclusive) gastric predilection.33,34
Our results are based on the study of the only individual featuring
a prominent diffuse stromal proliferation of GI wall from a PDGFRA-
mutant kindred we previously investigated.9 In absolute terms, this
constitutes a limitation to the significance of our conclusions. How-
ever, it must be considered that germline PDGFRA mutations are an
exceedingly rare event in humans, with only five to six examples (con-
sidering kindreds or single individuals) reported in the literature7,8; on
top of that, the presence of GI diffuse stromal proliferation together
with IFPs and/or GISTs, that is the ideal setting for investigating the
relationship between these latter tumours and TCs, has been reported
in a fraction only of mutants (in particular, with regard to the kindred
we previously published, only in the proband, that is member II-2-).8,9
The study of sporadic IFPs and PDGFRA-mutant GISTs is probably of
limited utility for defining a possible link between these tumours and
TCs as, under these circumstances, only the fully developed neoplastic
morphological and immunophenotypical characters of the former
tumours are observable, features which could be deemed not to be
specific enough in terms of cell lineage in the absence of any type of
transition with respect to physiological TCs
In conclusion, our results support TCs as the physiological coun-
terpart of both IFPs and PDGFRA-mutant GISTs, possibly patho-
genetically related to both of these tumour types. Furthermore, on
the basis of our results we herein propose “telocytoma” as a more
appropriate term than IFP for defining the lesion formerly referred
to as “Vanek’s tumour.” In fact, compared to the misleading “inflam-
matory fibroid polyp” definition that evokes an aspecific inflamma-
tory-reactive lesion, “telocytoma” conveys both the correct
pathogenetic (that is neoplastic) and histotypic (that is “telocytary”)
essence of this lesion (semantically reiterating the changeover from
“colonic fibroblastic polyp” to “colonic perineurioma” 35). Further
studies are warranted to further shed light on this fascinating topic.
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